drugset / Trial / NCT06445023
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.
Timeline
- Start
- 2024-07-11
- Primary completion
- 2026-10
- Completion
- 2027-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | barzolvolimab | Monoclonal antibody | 150 mg | Subcutaneous |
| Subject | barzolvolimab | Monoclonal antibody | 300 mg | Subcutaneous |